Dosing & Administration
Retatrutide is given as a once-weekly subcutaneous injection, and the single most important practical fact about it is…
How retatrutide is given in trials, and why dose escalation is everything
Retatrutide is given as a once-weekly subcutaneous injection, and the single most important practical fact about it is dose escalation: trials start low and step up slowly so the gut can adapt and nausea stays manageable. This unit explains the principles behind that schedule.
A blunt caveat first: this is education only. Retatrutide is investigational, there is no approved dosing label, and it cannot legally be used in compounding. Nothing here is a protocol to follow. The goal is to understand how the drug is administered in research, not to guide any personal use.
Key terms
The route and the weekly rhythm
In trials, retatrutide is injected under the skin once a week, the same rhythm as semaglutide and tirzepatide. The weekly schedule rests on the acylation from the molecule unit and the half-life it goes with, approximately 6 days in the phase 1b study. The phases below show the broad arc of a trial regimen.
The rhythm is simple in outline: one injection a week, ramped up gradually, with the protocol allowing a reduction if someone falls to a BMI of 22 or below. The exact steps are study-defined; the TRIUMPH-1 schedule is set out later in this unit. What matters conceptually is that the schedule is built around gentle, stepwise increases.
AdvancedWhy weekly, not daily
Weekly dosing is a tolerability and adherence win: fewer injections and steadier drug levels than a short-acting daily drug. What makes it possible is the half-life, approximately 6 days in phase 1b, and the phase 1 finding that the pharmacokinetic profile supported once-weekly dosing. The design behind that half-life is albumin binding: the discovery paper states that retatrutide's fatty diacid chain enables binding to albumin, a blood protein, as a half-life extension strategy, the same route tirzepatide and semaglutide take.